Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 56

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 56
---
 of the Combined Company’s employees, management and board of directors, and could have an adverse effect on its business,
financial condition and results of operations.

Risk related to Aptorum’s Preclinical and Clinical Development of Its Drug Candidates

We currently do not generate revenue from product sales and may never become profitable; unless we can raise more capital through additional financings, of which there can be no guarantee.

Our ability to generate revenue
and become profitable depends upon our ability to successfully complete the development of, and obtain the necessary regulatory approvals
for, the drug candidates in our Lead Projects and any future drug candidates we may develop, as we do not currently have any drugs that
are available for commercial sale. We expect to continue to incur losses before commercialization of our drug candidates and any future
drug candidates. None of our drug candidates has been approved for marketing in the U.S., Europe, the PRC or any other jurisdictions and
may never receive such approval. Our ability to generate revenue and achieve profitability is dependent on our ability to complete the
development of our drug candidates and any future drug candidates we develop in our portfolio, obtain necessary regulatory approvals,
and have our drugs products under development manufactured and successfully marketed, of which there can be no guarantee. We may not be
able to generate a profit until our drug candidates become profitable.

Even if we receive regulatory
approval and marketing authorization for one or more of our drug candidates or one or more of any future drug candidates for commercial
sale, a potential product may not generate revenue at all unless we are successful in:

| ● | developing a sustainable and scalable manufacturing process                                                                             
 for our drug candidates and any approved products, including establishing and maintaining commercially viable supply relationships with 
 third parties;                                                                                                                          |

| ● | launching and commercializing drug candidates following regulatory                             
 approvals and marketing authorizations, either directly or with a collaborator or distributor; |

| ● | obtaining market acceptance of our drug candidates as viable 
 treatment options;                                           |

<div align='center'>28</div>

| ● | addressing any competing technological and market developments; |

| ● | negotiating and maintaining favorable terms in any collaboration,                                                                     
 licensing or other arrangement into which we may enter to commercialize drug candidates for which we have obtained required approvals 
 and marketing authorizations; and                                                                                                     |

| ● | maintaining, protecting and expanding our portfolio of IP rights, 
 including patents, trade secrets and know-how.                    |

In addition, our ability to
achieve and maintain profitability depends on timing and the amount of expenses